![]() |
市場調查報告書
商品編碼
1477937
連續血糖監測系統市場預測:~2032 年Continuous Glucose Monitoring System Market Research Report Forecast till 2032 |
在預測期內,連續血糖監測系統市場規模預計將以 11.24% 的複合年增長率成長。
糖尿病盛行率的增加是推動全球連續血糖監測系統市場成長的一個突出因素。 患有糖尿病的人數正以驚人的速度增加,達到流行病的程度。 根據全球糖尿病聯盟 (IDF) 的數據,2021 年全球約有 5.37 億人患有糖尿病,預計到 2030 年這一數字將躍升至 6.43 億。 此外,根據美國糖尿病協會的數據,到 2021 年,將有 3,840 萬美國人(佔總人口的 11.6%)患有糖尿病。 1 型糖尿病影響著約 200 萬美國人,其中包括約 304,000 名兒童和青少年。 隨著糖尿病人口的持續增長,對有效的糖尿病管理解決方案的需求變得更加迫切。 連續血糖監測系統在即時瞭解血糖水平方面發揮著至關重要的作用,使患者和醫療保健專業人員能夠就治療和生活方式的改變做出及時、明智的決定。 連續血糖監測系統提供連續監測、早期異常檢測和個人化見解的能力滿足了不斷增長的糖尿病族群的需求。
區域見解
北美連續血糖監測系統市場預計到 2023 年將達到 30.7 億美元,在預測期內複合年增長率為 10.06%。
在技術進步和該地區糖尿病盛行率上升的推動下,北美的連續血糖監測系統市場正在經歷強勁增長。
由於技術進步、醫療成本增加和糖尿病盛行率增加,歐洲連續血糖監測系統市場佔據第二大市場。由於患者人數眾多、臨床試驗成本較低以及有利的監管政策,亞太地區連續血糖監測系統市場預計將在 2023 年至 2030 年期間成長最快。 此外,各大公司積極向該地區擴張也推動了該地區的市場成長。
本報告調查了全球連續血糖監測系統市場,提供了市場的定義和概述,分析了影響市場成長的因素和市場機會、市場規模、各個細分市場/地區/主要的趨勢和預測,它總結了細分:國家、競爭環境和主要公司概況。
Download PDF
Continuous Glucose Monitoring System Market is projected to register a CAGR of 11.24% during the review period.
The rising pervasiveness of diabetes overall stands apart as a conspicuous driver energizing the development of the worldwide continuous glucose monitoring systems market. Diabetes has arrived at plague extents, with a stunning ascent in the quantity of impacted people universally. As per the Global Diabetes Alliance (IDF), in 2021, roughly 537 million individuals overall were living with diabetes, and this number is supposed to take off to 643 million by 2030. Essentially, as per the American Diabetes Affiliation, diabetes impacted 38.4 million Americans, or 11.6% of the populace, in 2021. Type 1 diabetes influences around 2.0 million Americans, including roughly 304,000 youngsters and teenagers. The heightening rate of diabetes is ascribed to different elements, including stationary ways of life, unfortunate dietary propensities, and the maturing populace. As the diabetic populace keeps on developing, the interest for powerful diabetes the board arrangements turn out to be really squeezing. Continuous glucose monitoring systems assume a vital part in giving constant experiences into blood glucose levels, empowering patients and medical care experts to settle on convenient and informed choices in regard to therapy and way of life changes. The capacity of continuous glucose monitoring systems to offer continuous monitoring, early discovery of variances, and customized bits of knowledge lines up with the developing requirements of the extending diabetic populace.
Based on product the continuous glucose monitoring system market is divided into sensors and transmitter and receivers.
In terms of application, the market is classified into type 2 diabetes, type 1 diabetes, and non-diabetic patients.
Based on End user, the market has been divided into hospitals & clinics, homecare settings, and others.
Regional Insights
The North America continuous glucose monitoring systems market represented USD 3.07 billion out of 2023 and is projected to develop at a CAGR of 10.06% during the figure time frame. North America is additionally fragmented into the US, and Canada.
The North America continuous glucose monitoring systems market is encountering strong development, driven by mechanical progressions and a rising predominance of diabetes in the region.
Europe continuous glucose monitoring System market represented the second-biggest market share because of innovation progressions, expanding medical care consumption, and expanding pervasiveness of diabetes.
The Asia-Pacific Continuous Glucose Monitoring System market is supposed to be the quickest developing from 2023 to 2030 attributable to high persistent populace, decreased expenses of leading preliminaries, and good administrative arrangements. In addition, central participants working in the Continuous Glucose Monitoring System Market are effectively venturing into this region, further driving the regional market development.
Key Companies operating in the Continuous Glucose Monitoring System market are Dexcom, Inc (US), Menarini Diagnostics Srl (Italy), Senseonics (US), Medtrum Technologies Inc. (China), Nemaura Medical Inc (US), Ultrahuman Healthcare Pvt Ltd (India), Medtronic (Ireland), One Drop (US), Abbott Laboratories, Inc. (US), and Sinocare (China).
MARKET